| (Values in U.S. Thousands) | Dec, 2015 | Dec, 2014 | Dec, 2013 | Dec, 2012 | Dec, 2011 |
| Sales | 200 | 260 | 140 | 60 | 280 |
| Sales Growth | -23.08% | +85.71% | +133.34% | -78.57% | -36.36% |
| Net Income | -8,760 | -10,440 | -12,150 | -9,210 | -10,210 |
| Net Income Growth | +16.09% | +14.07% | -31.92% | +9.79% | +23.46% |
Venaxis Inc (APPY)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
Venaxis, Inc. is a biomedical diagnostic company focused on the clinical development and commercialization of its blood-based appendicitis test, APPY1. APPY1 is being developed initially for pediatric, adolescent and young adult patients with abdominal pain. Venaxis, Inc., formerly known as AspenBio Pharma, Inc., is based in Castle Rock, Colorado.